Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Opinion: Discussing the current HIV treatment landscape and specifically how other treatment options compare to Gilead Sciences' HIV treatments

Ticker(s): GILD

Who's the expert?

Institution: Lakeshore ID Associates

Chief of Infectious Diseases and Head of Infection Control at Amita Saint Joseph Hospital in Chicago, and a partner at Lakeshore Infectious Disease Associate
Infectious Disease specialist since 1997 with extensive clinical experience and currently treats 250 patients with HIV.
Particular areas of clinical interest include, bacterial infections (MRSA and others), tuberculosis, Clostridium difficile infections, viral infections, wounds and skin, bone and joint infections.

Interview Goal

Taking a look at pros and cons of the many treatment options Gilead Sciences has for HIV(Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, Truvada, Tybost, and Viread) and how they compare to other HIV treatment options or programs.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.